. 2019 Mar 15;10:186. doi: 10.3389/fgene.2019.00186

Table 5.

Meta-analysis of miR-149 rs2292832 and cancer risk.

		Homozygote (TT vs. CC)			Heterozygote (CT vs. CC)			Dominant (TT+CT vs. CC)			Recessive (TT vs. CT+CC)			Allelic (T vs. C)
Groups	Cases/Controls^a	OR^b (95% CI)	P^c	I²	OR^b (95% CI)	P^c	I²	OR^b (95% CI)	P^c	I²	OR^b (95% CI)	P^c	I²	OR^b (95% CI)	P^c	I²
All studies	15,954/19,594	0.89 (0.77–1.02)	<1e−4	64.2	0.96 (0.87–1.05)	0.008	37.1	1.00 (0.90– 1.11)	<1e−4	53.5	1.00 (0.92–1.08)	<1e−4	48.6	0.96 (0.88–1.04)	<1e−4	73.6
Controls in HWE^d	12,873/15,569	0.88 (0.75–1.04)	<1e−4	67	0.95 (0.89–1.02)	0.054	29.7	0.98 (0.87–1.09)	4e−4	50.8	0.98 (0.89–1.07)	<1e−4	51.3	095 (0.87–1.03)	<1e−4	70.8
QUALITY
High (>8)	15,149/18,939	0.98 (0.87–1.11)	<1e−4	52.8	0.94 (0.88–1.00)	0.060	27.4	0.97 (0.88–1.08)	1e−4	51.3	1.04 (0.96–1.13)	7e−4	47.3	1.02 (0.95–1.10)	<1e−4	66.3
Low (≤8)	805/655	1.32 (1.83–1.34)	0.183	35.7	1.25 (0.55–2.87)	0.043	59.3	1.31 (0.69– 2.48)	0.087	50.7	1.15 (0.90–1.46)	0.84	0	1.19 (0.98–1.4)	0.599	0^f
GENOTYPING
PCR–RFLP	9,437/11,117	1.05 (0.90–1.22)	0.003	46.6	1.01 (0.88–1.14)	0.016	39.5	1.06 (0.92–1.22)	3e−4	54.5	1.08 (0.98–1.19)	0.028	36.3	1.08 (0.98–1.18)	<1e−4	64.5
Others^e	6,517/8,477	0.94 (0.76–1.16)	9e−4	61.6	0.88 (0.79–0.98)	0.178	25	0.911 (0.77–1.06)	0.018	48.3	1.0 (0.88–1.13)	0.011	51.4	0.97 (0.88–1.08)	6e−4	62.8
ETHNICITIES
Asian	14,279/17,389	1.01 (0.89–1.15)	0.0001	51.9	0.97 (0.88–1.08)	0.006	40	0.97 (0.88–1.08)	0.006	40	1.05 (0.98–1.13)	0.005	40.6	1.05 (0.97–1.13)	<1e−4	65.1
Caucasians	1,675/2,205	0.98 (0.48–1.96)	0.022	64.9	0.93 (0.80–1.07)	0.30	16.5	0.94 (0.82–1.08)	0.13	43.5	1.04 (0.62–1.72)	0.052	57.4	0.95 (0.72–1.27)	0.049	57.9
CANCER CATEGORIES
GI	6,508/8,150	0.96 (0.83–1.12)	0.043	36.9	0.87 (0.79–0.97)	0.57	0	0.92 (0.84–1.01)	0.206	19.2	1.07 (0.99–1.15)	0.079	31.5	1.01 (0.94–1.10)	0.010	46
HNC	2,885/3,769	1.35 (0.76–2.38)	0.003	68.6	1.34 (0.82–2.19)	0.001	72.2	1.45 (0.86–2.42)	<1e−4	80.3	1.10 (0.97–1.24)	0.096	44.2	1.30 (0.87–1.94)	<1e−4	82.8
Others	6,561/7,675	0.96 (0.78–1.19)	0.001	59.5	0.97 (0.88–1.06)	0.126	30.4	0.98 (0.83–1.15)	0.010	51.9	0.99 (0.87–1.13)	0.011	51.5	0.99 (0.89–1.11)	2e−4	65.5
CANCER TYPES
BC^e	1,871/1,894	1.12 (0.53–2.36)	0.014	71.6	1.02 (0.87–1.19)	0.192	36.7	1.07 (0.59–1.93)	0.031	65.9	1.10 (0.68–1.77)	0.063	58.8	1.05 (0.69–1.60)	0.005	76.4
HCC	2,512/3,107	0.95 (0.68–1.34)	0.008	61	0.91 (0.78–1.06)	0.285	17.7	0.93 (0.72–1.20)	0.039	50.6	0.97 (0.86–1.09)	0.049	48.5	0.99 (0.83–1.17)	0.003	65.6
GC	2,527/3,399	0.95 (0.79–1.14)	0.323	13.6	0.85 (0.72–1.00)	0.493	0	0.92 (0.79–1.07)	0.397	4.2	1.08 (0.96–1.22)	0.319	14.2	1.01 (0.93–1.10)	0.194	29.2
CRC^e	1,469/1,644	1.10 (0.86–1.40)	0.671	0	0.85 (0.67–1.07)	0.615	0	0.97 (0.78–1.20)	0.704	0	1.21 (1.04–1.40)	0.748	0	1.10 (0.98–1.23)	0.801	0
LC	1,714/1,559	1.04 (0.8246–1.31)	0.116	53.5	1.03 (0.83–1.29)	0.602	0	1.04 (0.84–1.29)	0.351	4.3	0.98 (0.85–1.13)	0.175	42.4	1.04 (0.70–1.52)	0.157	45.8
Others	5,861/7,991	1.02 (0.77–1.34)	2e−4	65.2	1.071 (0.84–1.36)	5e−4	63.5	1.10 (0.85–1.44)	<1e−4	73.5	1.00 (0.86–1.16)	0.012	50.7	1.07 (0.89–1.29)	<1e−4	77.9

The overall, HWD-sensitivity and subgroup analyses.

n represents number of cases and controls in each group.

Pooled ORs and 95% confidence intervals.

P-value of the heterogeneity test.

Meta-analysis of all studies excluding those with the control group not in HWE.

These subgroups were found to be influenced by departure from HWE. Please refer to the Supplementary Table S4 for details on HWD sensitivity and adjustment analysis for these subgroups.

Although the point estimate of I² was zero for the allele contrast in the low quality subgroup, the random effect model was used based on the 95%CI of I² (0–69.8%) and small number of studies.

GI, Gastrointestinal tract cancers; HNC, Head and neck cancers; BC, Breast cancer; HCC, Hepatocellular cancers; GC, Gastric cancer; CRC, Colorectal cancer; LC, Lung cancer.

Significant associations are shown in boldface.